Related Experiment Video
Updated: May 18, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
Cardiac amyloidosis: Disease overview and novel pathophysiologic insights
Gregorio Tersalvi1, Daniela Tomasoni2, Roxanne Coderre1
1Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA.
None:
Cardiac amyloidosis (CA) has transitioned from a rare, frequently fatal disease to an increasingly recognized cause of heart failure, driven by heightened awareness, noninvasive diagnostic strategies, and the advent of disease-modifying therapies. As a result, molecular imaging has become central to contemporary management by providing signals that reflect underlying disease biology. Transthyretin CA predominantly involves progressive extracellular fibril accumulation causing myocardial stiffening, whereas light-chain CA is characterized by early myocardial dysfunction mediated by direct proteotoxic effects of circulating light chains in addition to extracellular fibril accumulation. These divergent mechanisms may underlie different behaviors of diagnostic imaging such as bone-avid scintigraphy and β-sheet-binding positron emission tomography tracers. In this compendium review, we integrate pathophysiological insights across major and rarer amyloid subtypes with nuclear imaging and contextualize these mechanisms through clinical phenotypes, red flags, and risk stratification tools.
Related Concept Videos
Cardiomyopathy I: Introduction and Classification
Coronary Artery Disease II: Pathophysiology
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Cardiomyopathy IV: Restrictive Cardiomyopathy

